Aims: This two-part, double-blind, double-dummy, randomized, placebo-controlled trial (83 sites) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg and linagliptin (Lina) 5 mg fixed-dose combinations (FDCs) in Japanese patients with type 2 diabetes mellitus (T2DM) who were poorly controlled with Empa. Results: Change from baseline in HbA1c at Week 24 was greater (P < 0.0001) with Empa/Lina than with Empa/Plc (primary outcome, Empa/Lina 10/5: −0.94 vs −0.12%; adjusted mean difference, −0.82%; Empa/Lina 25/5: −0.91 vs −0.33%; adjusted mean difference, −0.59%). Over 24-and 52-week periods, higher proportions of patients achieved HbA1c < 7.0% and greater decreases in fasting plasma glucose were observed with Empa/Lina compared with Empa/Plc. Empa/Lina was well tolerated, with no unexpected adverse events or diabetic ketoacidosis. One case of confirmed hypoglycaemia with Empa/Plc 25/5 was reported.
inhibit renal glucose reabsorption, resulting in increased urinary excretion of glucose and thereby reducing plasma glucose levels in an insulinindependent manner. 1 SGLT2 inhibitors also reduce body weight and blood pressure. 1 Empagliflozin, in particular, also reduces the risk of cardiovascular mortality and is associated with slower progression of kidney disease, based on surrogate markers, that is, progression to macroalbuminuria and doubling of serum creatinine level, and lower rates of renal events compared with placebo in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease. 2, 3 DPP-4 inhibitors augment the glucose-stimulated secretion of insulin 4 and are associated with low incidence of hypoglycaemia and weight neutrality. 5 Linagliptin is one of the few DDP-4 inhibitors that does not require dose adjustment in patients with hepatic/renal impairment. 6 Because of the complementary mechanisms of action of SGLT2 and DPP-4 inhibitors, dual therapy improves glycaemic control in patients with T2DM without increasing the risk of hypoglycaemia or weight gain, 4 and fixed-dose combinations had not received antidiabetic therapy for approximately 12 weeks and in patients using metformin. [8] [9] [10] The objective of this two-part study was to evaluate the efficacy and safety of Empa/Lina FDC in Japanese patients with T2DM who switched from empagliflozin monotherapy.
| MATERIALS AND METHODS

| Study details
This was a 2-part, multicentre, phase III, randomized, double-blind, 
| Study population
Male and female adults (≥ 20 years) with a diagnosis of T2DM were eligible if they were on a diet and exercise regimen for ≥ 12 weeks and were either drug-naive (ie, no antidiabetic drug ≥ 12 weeks) or were using a stable dosage of one oral antidiabetic drug (OAD) (sulfonylurea up to half the maximum approved dosage) for ≥ 12 weeks (≥ 18 weeks for thiazolidinedione) but discontinued the OAD at screen- 
| Study design
All Empa and Empa/Lina FDC tablets were provided by Boehringer
Ingelheim Pharma GmbH & Co. KG (Germany) and were taken orally once daily in the morning. Patients were randomized by a computergenerated random sequence using a phone/web-based interactive response system. Randomization was stratified by HbA1c (< 8.5 or ≥ 8.5%), eGFR (≥ 45 and < 60, ≥ 60 and < 90, or ≥ 90 mL/min/1.73 m 2 ) and prior OAD use (yes, no).
| Open-label stabilization period
Patients who met inclusion criteria after screening were randomized 1:1 to receive Empa 10 mg (Part A) or 25 mg (Part B) for 16 weeks ( Figure S1 in Supporting information).
| Placebo run-in period
Patients who completed the stabilization period entered a 2-week run-in period and received Empa 10 mg plus placebo for Empa/Lina 10/5 (Part A) or Empa 25 mg plus placebo for Empa/Lina 25/5 (Part B).
| Double-blind treatment period
A double-dummy design (two tablets/d) was used to maintain blinding. At the end of the run-in period, patients with HbA1c ≥ 7.5 to ≤ 10.0%, who still satisfied inclusion/exclusion criteria were random- were adjudicated by independent external committees.
| Efficacy outcome measures
| Statistical analysis
Based on previous experience, the between-group difference in change in
HbA1c from baseline at Week 24 was assumed to be 0.5%, with a standard deviation (SD) of 1.1%. Assuming 3% of patients would be ineligible for the full analysis set (FAS, defined as all randomized patients who received ≥ 1 dose of study drug and underwent both baseline and ≥ 1 ontreatment HbA1c assessment), 106 randomized patients per study arm would provide 90% power for the primary endpoint for each part. Assuming 12% of randomized patients in Part B discontinued during the 52-week treatment period, 114 patients per study arm would ensure that at least 100 patients were treated for the full year, as required by the Japanese Pharmaceuticals and Medical Devices Agency.
The primary endpoint was analysed using a restricted maximum after the last intake of study drug were analysed. Two-sided P values < 0.05 were considered significant. Statistical analyses were performed using SAS Version 9.4 (SAS Institute Inc., Cary, North Carolina).
3 | RESULTS
| Patient disposition
Of 
| Demographic and baseline clinical characteristics
In Parts A and B, demographic and baseline clinical characteristics were generally balanced between groups (Table 1) 
| Change in HbA1c
Compared with Empa/Plc, Empa/Lina treatment resulted in significantly greater decreases in HbA1c at Weeks 24 (primary endpoint) and 52. In the double-blind treatment period ( Figures S6, S7 ). Fewer patients receiving Empa/Lina, compared with those receiving Empa/Plc, required rescue medication at Weeks 24 and 52 ( Figure S8 ).
| Safety and tolerability measures
The overall incidence of AEs, as well as the incidence of drug-related AEs and AEs leading to discontinuation, was lower with Empa/Lina 10/5 than with Empa/Plc 10/5 over 24 weeks, but was higher with Empa/Lina 25/5 than with Empa/Plc 25/5 over 52 weeks (Table 2) .
Most AEs were mild or moderate in intensity. During the double-blind treatment periods, the rate of SAEs was slightly higher in the Empa/ Plc groups than in the Empa/Lina groups. No SAEs were assessed as drug-related, with the exception of one event (drug-induced liver injury in the Empa/Lina 25/5 group) (Table S1 in Supporting information) and no deaths were reported. There were no DKA events confirmed by an independent central adjudication committee. Consistent with previous studies in non-Japanese patients, 8, 9, 11 reductions in HbA1c with Empa/Lina FDC in our study were superior to those with empagliflozin monotherapy. Although study differences preclude direct comparison, reductions in HbA1c with Empa/Lina FDC vs empagliflozin monotherapy in our Japanese study population appear to be more pronounced than those in non-Japanese patients. 8, 11 This may reflect the increased HbA1c-lowering efficacy of DPP-4 inhibitors in Asian patients compared with non-Asian patients. 12, 13 Decreases in FPG concentrations were consistent with the observed reductions in HbA1c.
As patients were pre-treated with empagliflozin monotherapy before the double-blind treatment period, other efficacy endpoints (SBP, DBP and body weight) were not substantially different with Empa/Lina FDC compared with empagliflozin monotherapy. Linagliptin is known to be neutral for these variables, 5 and changes were not expected by adding linagliptin to empagliflozin. 8,9,11 Modest increases in body weight were observed with Empa/Lina FDC compared with empagliflozin monotherapy; however, body weight in the Empa/Lina FDC group remained lower than that at initiation of open-label empagliflozin monotherapy.
Our findings indicate that Empa/Lina FDC is generally well tolerated in Japanese patients with T2DM, similar to findings concerning patients from other countries. [8] [9] [10] [11] There were no new AEs or overall increased risk of AEs in Japanese patients with T2DM who received linagliptin as add-on to empagliflozin and no notable trend in the frequency of AEs with long-term treatment at the higher empagliflozin dose. Urinary and genital infection events, known to be associated with SGLT2 inhibitors, 14 were similar in both groups. No patients treated with Empa/Lina FDC experienced any confirmed hypoglycaemic episodes, indicating that better glycaemic control was achieved by the addition of linagliptin without increased risk of hypoglycaemia, consistent with the low risk of hypoglycaemia observed previously. [8] [9] [10] [11] Metabolic acidosis and ketoacidosis events were not reported in trials with Empa/Lina FDC in non-Japanese patients with T2DM. [8] [9] [10] [11] In the current study, mild, non-serious events, categorized as increased ketogenesis, metabolic acidosis or DKA were observed in all treatment groups; most events were blood ketone body increased.
However, none of these events was adjudicated as DKA by the independent adjudication committee, consistent with previous results concerning the use of combined SGLT2 inhibitors and DPP-4 inhibitors in Japanese patients. [15] [16] [17] Although no cardiac failure events were reported, two adjudicated cardiovascular events occurred in one patient each in the Empa/Plc 10/5 and Empa/Lina 25/5 groups. Empagliflozin is associated with reduced cardiovascular mortality, all-cause mortality and hospitalization for heart failure in patients with T2DM. 21 In the current study, although fasting plasma glucagon levels were slightly increased in the FDC groups, these minimal increases were considered not to be clinically significant because of the wide individual variations. Moreover, postprandial glucagon suppression has been suggested to be more important than fasting glucagon suppression for glycaemic control with DPP-4 inhibitors. 22 Further evaluations of insulin/glucagon ratios, amino acid metabolism and endogenous glucose production are needed. Data are presented as n (%) of patients who received ≥ 1 dose of study drug. a Hypoglycaemic AE accompanied by a plasma glucose level ≤ 70 mg/dL (≤ 3.9 mmol/L) or the need of assistance. b AST and/or ALT ≥ 3-fold ULN combined with total bilirubin ≥ 2-fold ULN, or AST and/or ALT ≥ 5-fold ULN. One patient in the Empa/Plc 10/5 group met the definition of protocol-specified hepatic injury, but was not included because the liver function disorder was considered to be associated with concurrent pancreatic carcinoma and not an additional event. An additional patient in the Empa/Plc 10/5 group had investigator-defined "cholangitis". One patient in the Empa/Lina 25/5 group met the definition of protocol-specified hepatic injury, however, was later diagnosed with hepatitis E, which was considered to be the cause of the elevated liver enzymes and unrelated to study drug. c Preferred terms included "pollakiuria", "polyuria" and "nocturia". d One patient in the Empa/Plc 10/5 group had pancreatic carcinoma during the post-treatment period. e Preferred terms included "acetonemia", "acidosis", "anion gap abnormal", "anion gap increased", "blood pH abnormal", "blood pH decreased", "diabetic hyperglycaemic coma", "ketonuria", "ketosis", "Kussmaul respiration", "metabolic acidosis", "blood ketone body", "blood ketone body increased", "urine ketone body present", "blood ketone body present", "urine ketone body", and "diabetic metabolic decompensation". Most observed events were "blood ketone body increased"; there was one event of "acetonemia" in the Empa/Plc 10/5 group, 2 events of "ketosis" in the Empa/Lina 25/5 group, and two events of "urine ketone body present" in the Empa/Lina 25/5 group. All events were mild and non-serious. f Preferred terms included "diabetic ketoacidosis", "diabetic ketoacidotic hyperglycaemic coma", and "ketoacidosis".
T2DM. In countries such as Japan, where metformin is not the first choice for T2DM management, Empa/Lina combination therapy may provide better efficacy than monotherapy with empagliflozin or linagliptin, with an expected improvement in patient adherence to treatment.
